Director, Radiobiology Program
Cross Cancer Institute

The Cross Cancer Institute, the comprehensive cancer treatment and research facility of northern Alberta, located in Edmonton, is seeking a Director of its Radiobiology Program. The Program has four principal investigators in addition to the Director, and occupies a total of 6700 square feet. Collaboration with radiation oncologists and access to clinical material are facilitated by the close relationship between the Radiobiology Program and the Department of Radiation Oncology. Currently research interests of Program members include: DNA damage and repair, tumor hypoxia, radiation injury in lung, radioprotection of bone marrow and other normal tissues, and cellular radiosensitivity of human tumor biopsies. The salaries of all principal investigators and some infrastructure support are provided by the Institute. The Cross Cancer Institute is affiliated with the adjacent University of Alberta and participates in the academic activities of the University. The Institute has embarked on a major expansion project, which will expand the laboratory research facilities to approximately 35,000 net square feet, with an occupancy date of May, 1992. Radiobiology and related clinical research programs will occupy one-third of this space.

The successful candidate will have a strong track record in independent research, will be suitable for an academic appointment at the level of associate or full professor and will have the vision, energy and leadership skills necessary to direct a vigorous research group. Interested persons should send their curriculum vitae, a synopsis of previous and proposed research, and the names of three referees to: Dr. A.L.A. Fields, Director, Cross Cancer Institute, 11560 University Ave., Edmonton, Alberta T6G 1Z2.

To assure full consideration, applications should be received by July 31. The Cross Cancer Institute is an equal opportunity employer. In keeping with Canadian immigration regulations, this advertisement is directed toward Canadian citizens and permanent residents; however, others are strongly urged to apply.

Our Institute is a smoke free workplace.

UNIVERSITY OF HAWAI'I, CANCER RESEARCH CENTER OF HAWAI'I
TWO TENURE TRACK POSITIONS FOR RESEARCH MEDICAL ONCOLOGISTS

The University of Hawaii Cancer Research Center of Hawaii is seeking applications from medical oncologists for two tenure track faculty positions in the Center’s Clinical Research–Cancer Control Program.

The Center conducts clinical cancer research and cancer control research for participation by all cancer health care professionals in Hawaii. The Center maintains full membership in SWOG and NSABP and a satellite relationship with POG. In addition, local studies are developed to build on programmatic strengths in areas such as liver cancer, gastric cancer, natural products, and biology. Cancer control research is focused on special underserved groups in Hawaii's multiethnic and multicultural population. The Center is responsible for providing educational, administrative and scientific support for all studies introduced into the community. Integrating laboratory research conducted at the Center into clinical studies is an essential activity. Faculty provide scientific direction to the program and generate national cooperative group and local study protocols.

It is anticipated that the successful candidate will also hold a teaching appointment in the Division of Oncology, Department of Medicine, John A. Burns School of Medicine and participate in a teaching–research oncology practice focused on special populations.

PROGRAM DIRECTOR

Applicants should have a record of accomplishment in clinical cancer research and teaching. They should have demonstrated organizational and administrative abilities and good communication skills.

Minimal requirements include an M.D. degree, board certification or equivalent in medical oncology and at least seven years of relevant experience. Rank and salary will be commensurate with experience.

RESEARCH MEDICAL ONCOLOGIST

Applicants should have experience in conducting clinical research studies and demonstrated teaching abilities. Applicants should also have laboratory research experience in pharmacology or cellular and molecular biology. Alternatively an active involvement in epidemiology or prevention and control research would also be encouraged. Minimum requirements include an M.D. degree, board certification or equivalent in medical oncology and at least three years of relevant experience. Rank and salary will be commensurate with experience. Interested applicants for the above positions should send a curriculum vitae and a list of three persons from whom references can be obtained to: Brian F. Issell, M.D., Director, Cancer Research Center of Hawaii, 1236 Lauhala Street, Honolulu, HI 96813. Closing Date: August 31, 1990 or until positions are filled.
The winner of the 1990 Bristol-Myers Squibb Award is Bert Vogelstein, M.D., Professor of Oncology and Director of the Molecular Genetics Laboratory at Johns Hopkins University School of Medicine. This award, given for distinguished achievement in cancer research, recognizes his landmark contributions to knowledge of the genetic alterations occurring in the development of human colon cancer. The award selection committee is an international body of 12 members, headed by Alan Sartorelli of Yale University School of Medicine. Dr. Vogelstein and colleagues' original discovery of mutated ras oncogenes in colon cancer was recognized previously on a Cancer Research cover (June 1, 1988).

Involved in the sequential development of human colon cancer are the activation of one or more oncogenes and the inactivation of several suppressor genes. Individuals at high risk for colon cancer are thought to inherit certain suppressor genes. According to Dr. Vogelstein, the progression from benign polyps to malignant tumors, and ultimately to metastases, results from an accumulation of these alterations occurring over many years.

Three of the genes thus far discovered to be important in colon cancer growth are likely to be suppressor genes, one of which is the p53 gene on chromosome 17. This gene is altered also in other common tumors, such as those of the breast, lung, and brain. Dr. Vogelstein's group recently observed a gene to be missing or altered on chromosome 18. This gene, called DCC, for "deleted in colorectal carcinoma," encodes a protein structurally similar to certain cell adhesion proteins. The loss in cell-to-cell binding caused by deletion of this gene could disrupt growth control and allow escape of neoplastic cells to other organs.

In addition to his work on colon cancer, Dr. Vogelstein has a major interest in the pathogenesis of brain tumors. He and his associates have recently described a new family of genes, the "GLI" family, which play a role in this tumor type. Much of Dr. Vogelstein's work on colon and brain tumors involves the application of recombinant DNA technology to the study of primary human tumors removed at surgery. A review of his work appeared in the June 1990 issue of Cell.

Dr. Vogelstein received the M.D. degree in 1974 from Johns Hopkins, and, after pediatric internship and residency there, he spent two years as a research associate in tumor biology at the National Cancer Institute. He returned to Johns Hopkins as assistant professor of oncology in 1978 and was made full professor in 1989. He has been honored widely, including the Allison Eberlein Award for outstanding contributions to leukemia research, the Merit Award of the National Cancer Institute, and the Rhoads Memorial Award of the American Association for Cancer Research. He has served on several NIH study sections and is an associate editor of Cancer Research.

We are indebted to Liza Fields of Bristol-Myers for the photograph and to Dr. Vogelstein for information provided.

Sidney Weinhouse